Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Integra LifeSciences Returns To Organic Growth After Rough Year With COVID-19

Executive Summary

Integra's first-quarter revenue was up less than 3%, year over year, but the company reported the integration of the ACell regenerative technology business is ahead of schedule

You may also be interested in...



JPM 2021: Conformis Announces ACS Knee For 2H 2021, Integra Weathers Pandemic

The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the final day of the meeting.

Integra Adds ACell’s Regenerative Tech As It Dumps Extremity Orthopedics

Integra will pay up to $400m for ACell to expand its wound management and soft-tissue repair product line. The deal is part of a larger restructuring plan that includes selling its orthopedics business.

Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial

Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel